Health Technology Assessment

All Items

• Cost-effectiveness analysis of dupilumab for the treatment of severe atopic dermatitis in adults in Italy Analisi costo-utilità di dupilumab per il trattamento della dermatite atopica grave negli adulti in Italia

  Antonio Costanzo, Gianluca Furneri, Rossella Bitonti, Maria Paola Pedone, Francesca Fanelli, Roberta Di Turi

  57-65

  DOI: https://doi.org/10.33393/grhta.2020.710

• Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study

  Gregorio Carretero, David Moreno, Almudena González Domínguez, David Trigos, Albert Ledesma, Esther Sarquella, María Merino, Carles Blanch, SROI Psoriasis Group

  50-56

  DOI: https://doi.org/10.33393/grhta.2020.2146

• Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B

  Andrea Aiello, Maria Elisa Mancuso, Alessio Colombo, Cristina Teruzzi, Patrizia Berto

  40-49

  DOI: https://doi.org/10.33393/grhta.2020.2113

• The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service

  Claudio Jommi, Filippo Cipriani, Francesca Fanelli, Maria Paola Pedone, Walter Canonica

  33-39

  DOI: https://doi.org/10.33393/grhta.2020.2139

• Evaluation of the use of Floseal®, a topical hemostatic agent, in cardiothoracic surgery

  Rossella Di Bidino, Luz Irene Urbina, Marco Oradei, Amerigo Cicchetti

  14-25

  DOI: https://doi.org/10.33393/grhta.2020.695

• A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer

  Eugenio Di Brino, Matteo Ruggeri, Stefania Boccia, Nicoletta Cerana, Domenica Lorusso, Dario Sacchini, Antonella Savarese, Liliana Varesco, Americo Cicchetti

  1-8

  DOI: https://doi.org/10.33393/grhta.2020.557